Report: The Right Shot – Bringing down barriers to affordable and adapted vaccines
According to MSF, the report shows how vaccine prices are affected by the lack of competition among vaccine manufacturers, procurement and purchasing strategies, and pharmaceutical practices.
The report also highlights that the South African government continues to pay high prices for the human papillomavirus (HPV) vaccine being rolled out through the nation’s schools.
According to the report, the Department of Health negotiated a significantly reduced price of R157 per dose of GlaxoSmithKline two-dose vaccine Cervarix. However, the MSF report notes that this price is still three times more than the price at which lower income countries receive the vaccine through the international financing mechanism GAVI.
The report quotes Department of Health Deputy Director General Yogan Pillay, who describes why South Africa pays a high price for the vaccine meant to reduce women’s risks of cervical cancer.
“We introduced two new vaccines recently (PCV and HPV) … and because there are only two suppliers for each vaccine, there’s no competition and we pay a premium… To the extent that we know what other countries are paying, that would strengthen our arm [in negotiations with companies].”
Adding the HPV vaccine to the South African immunisation schedule pushed up the cost of fully vaccinating a girl in South Africa by about 18 percent – from about R1,115.00 to over R1,363.00 per girl, according to MSF.
The report argues that with reduced HPV vaccine prices, the Department of Health could dramatically increase eligibility criteria for the vaccine to all girls aged 9-14 years.
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Report: The Right Shot – Bringing down barriers to affordable and adapted vaccines
by healthe, Health-e News
January 22, 2015